奈达铂同步放化疗治疗局部晚期宫颈癌的临床研究  

Clinical study of nedaplatin chemoradiotherapy for locally advanced cervical cancer

作　　者：陈静[1] 陆谔梅[1] 黄健[1] Chen Jing et al(Department of Radiotherapy, Jiangsu Cancer Hospital, Nanjing 210009, China)

机构地区：[1]江苏省肿瘤医院放疗科,南京210009

出　　处：《齐齐哈尔医学院学报》2016年第34期4333-4335,共3页Journal of Qiqihar Medical University

摘　　要：目的探讨奈达铂同步放化疗治疗局部晚期宫颈癌的临床疗效。方法选择2009年1月至2012年1月期间本院行同步放化疗治疗的70例局部晚期宫颈癌患者作为研究对象,随机分为对照组和观察组,各35例。观察组采用奈达铂同步放化疗,对照组采用顺铂同步放化疗,观察两组治疗后近期疗效情况,并监测两组不良反应情况。结果两组近期疗效比较:观察组局部晚期宫颈癌患者客观有效率(62.86%)和疾病控制率(91.43%)显著高于对照组(37.14%,68.57%),组间差异具有统计学意义(P<0.05)。观察组不良反应发生率(20.0%)低于对照组(37.14%),但组间差异无统计学意义(P>0.05)。结论局部晚期宫颈癌采用奈达铂同步放化疗方案近期临床疗效较好,且不良反应风险相对较低,临床应用安全可靠。Objective To investigate the clinical efficacy of nedaplatin chemoradiotherapy for locally advanced cervical cancer. Methods 50 patients with locally advanced cervical cancer in our hospital from January 2009 to January 2012 were randomly divided into control group and observation group, 25 cases in each group. The observation group adopted radiotherapy and nedaplatin chemotherapy, control group with radiotherapy and cisplatin chemotherapy. Efficacy recently observed in the two groups after treatment, and monitored of adverse reactions of the two groups. Results Short-term efficacy comparison of the two groups： the observation group of locally advanced cervical cancer patients with objective effective rate （ 52% ） and disease control rate （ 84% ） was significantly higher than that of the control group （36%, 68%）, the difference between groups was statistically significant （P〈0. 05）. The incidence rate of adverse reaction in the observation group （20%） was significantly lower than that of the control group （36%）, The difference between groups was statistically significant （P〈0.05）. Conclusions Radiotherapy and chemotherapy with nedaplatin applied on patients with locally advanced cervical cancer has better clinical efficacy, the risk of adverse reactions is relatively low, safe and reliable in clinical application.

关 键 词：局部晚期宫颈癌 奈达铂 临床疗效 安全性 

分 类 号：R737.330.5[医药卫生—肿瘤]